The LCCC Cancer Grand Rounds works with a multidisciplinary team of healthcare professionals, representatives, and leaders to produce the Cancer Grand Rounds.


Our Planning Committee determines what knowledge gaps exist for our primarily North Carolina user base. Grand Rounds planning committee members work to select the topics and presenters throughout the year.

 

2025 LCCC Cancer Grand Rounds Planning Committee:

Course Directors

Jared Weiss, MD1Deborah Marie Stephens, DO2Kaitlin Morrison, PhD

Committee Members

Jared Weiss, MD1Deborah Marie Stephens, DO2Kaitlin Morrison, PhD
Victoria Bae-Jump, MD, PhD3Megan McElfresh, PA-CTatjana Grgic, PharmD, BCOP, CPP
Gaorav Gupta, MD, PhD4Dominique Higgins, MD, PhD5Lee Jamison, MD
Cecilia Levandowski, MD, PhDMihir Patel, MD6Kimberly Riddick, BSN, RN, NPD-BC
Andrew Smitherman, MD, MScPhilip Spanheimer, MDPatty Spears, BS, FASCO
Mary Beth Westerman, MD6

 

Financial Disclosures

  1. Dr. Weiss is a stockholder in Vesselon, Nuvalent, En Fuego Therapeutics, Vertex, Merus, Revmed; receives consulting fees from AZ, EMD Serono, Nanobiotix, PDS, Amgen, Pharmacosmos, GSK; and receives research grants from Pharmacosmos, Loxo, PDS, Genmab, Iovance, Nurix, TSCAN, Janus, BMS, Summit.
  2. Dr. Stephens has served on advisory boards for Abbvie, AstraZeneca, BeOne, BMS, Genentech, Pfizer, Pharmacyclics, J&J. These were one time consulting efforts, but she is asked periodically to serve on additional boards. She is a consultant for Abbvie and this is an ongoing relationship. She has also received research grants research grants to Lineberger Comprehensive Cancer Center from BeOne, which are ongoing.
  3. Dr. Bae-Jump is on the Data Safety Monitoring Board for Gilead (2025 to present) and received a research grant from Merck (ended January 2024).
  4. Dr. Gupta holds stock in Naveris, Inc., receives a research grant from Merck and Co. (until 6/2026), and received a research grant from Breakpoint Therapeutics (ended 12/2024).
  5. Dr. Higgins holds ownership interest in Ackey Therapeutics (CEO/founder), holds stock in Ackey Therapeutics, and receives speaker and consulting fees from Medtronic.
  6. Dr. Patel receives speaker fees from Intuitive Surgical and consulting fees from Johnson & Johnson.
  7. Dr. Westerman receives consulting fees from CG Oncology.
  8. These activities have been planned and implemented under the sole supervision of the Course Directors, Jared Weiss, MD, and Deborah Marie Stephens, DO of the UNC School of Medicine, and the planning committee in association with the UNC Office of Continuing Professional Development (CPD). Dr. Stephens has served on advisory boards for Abbvie, AstraZeneca, BeOne, BMS, Genentech, Pfizer, Pharmacyclics, J&J. These were one time consulting efforts, but she is asked periodically to serve on additional boards. She is a consultant for Abbvie and this is an ongoing relationship. She has also received research grants research grants to Lineberger Comprehensive Cancer Center from BeOne, which are ongoing. CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME. The planning committee members and their relevant financial relationships with ineligible companies as defined by the ACCME can be found at https://learn.unclcn.org/content/unclcn-webinar-planning-committee